Skip to main content

Advertisement

Table 1 Key NICE guideline recommendations relating to risk-based early detection and prevention strategies

From: Can the breast screening appointment be used to provide risk assessment and prevention advice?

Early detection and prevention strategies Moderate risk Lifetime risk 17 % to 29 % High risk Lifetime risk 30 % + 10-year risk 8 %+ Gene carriers and 30-50 % likelihood for TP53, BRCA1, or BRCA2
10-year risk 3 % to 7.9 % from age 40 to 49 years
Mammography Annual from age 40 to 49 Annual from age 40 to 59 Annual from age 40 to 69 except TP53
Magnetic resonance imaging N/A N/A Annual from age 30 to 49, 25 to 59 for TP53
Tamoxifen Consider 5 years of 20 mg daily Offer 5 years of 20 mg daily Offer 5 years of 20 mg daily
Raloxifene (post-menopausal) Consider 5 years of 60 mg daily Offer 5 years of 60 mg daily Offer 5 years of 60 mg daily
  1. N/A, not applicable; NICE, National Institute of Health and Care Excellence